For further information concerning Lilly grant funding,
visit www.lillygrantoffice.com.
Results from LUMINA trial showing very low local recurrence rate with omission of radiotherapy after breast-conserving surgery in patients with low-risk luminal A breast cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)
Exploratory analysis of EFS by residual cancer burden from KEYNOTE-522 evaluating neoadj pembrolizumab plus chemotherapy followed by adj pembrolizumab for early-stage TNBC, presented at ASCO 2022 and reported by Clinical Care Options (CCO)
PALOMA-2 study: final OS analysis with palbociclib plus letrozole in ER-positive/HER2-negative advanced breast cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)
Gain expert insight on managing NTRK- and RET-altered malignancies and optimal methods for detecting gene fusions, in this webcast from Clinical Care Options (CCO)
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.